Drug Portfolio.

AIkido Pharma Inc. is focused on the treatment of four cancers, prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

AIkido Pharma also has an Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus, from the University of Maryland Baltimore.

About AIkido Pharma.

AIkido Pharma Inc. is a biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. The AIkido Pharma Inc. platform contains patented technology from leading universities and researchers and we seek to develop our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our prostate and pancreatic treatment has shown positive preclinical results.

GET

Email Alerts.

Receive the latest news & events.

Latest News.

Market Data copyright © 2020 LimeGoat. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.